Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 25C-NBF
Research chemicalResearch chemicalPhenethylaminePsychedelic5-HT2A agonistN-benzyl (NBF)

25C-NBF

Also known as 2C-C-NBF · NBF-2C-C

25C-NBF is the N-(2-fluorobenzyl) derivative of 2C-C, part of the NBF series of N-benzyl phenethylamine psychedelics. It is a potent 5-HT2A agonist active in the sub-milligram range and shares the narrow safety margin, vasoconstriction and seizure risk of the broader 25x family.

01 Overview

25C-NBF belongs to the NBF subfamily, in which the N-benzyl group bears a 2-fluoro substituent instead of the 2-methoxy of NBOMe. It has appeared on blotter research-chemical markets and in seized samples.

Human data are anecdotal only. NBF compounds are broadly comparable in potency and risk to NBOMes, and 25C-NBF carries the full class hazards of vasoconstriction and serotonergic overstimulation.

02 Mechanism

Potent agonist at serotonin 5-HT2A receptors; the N-2-fluorobenzyl group confers high 5-HT2A affinity on the 2C-C scaffold.

03 Dosing

TierDoseRouteNotes
Threshold200–500 µgSublingualEstimated; sparse data.
Common500–1500 µgSublingualAnecdotal only.

04 Effects

EffectMagnitudeEvidence
Psychedelic effectsVisuals and cognitive alteration consistent with the 25x class.6-10 hAnecdotal
StimulationBody load, tension and restlessness.markedAnecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
VasoconstrictionCold, painful extremities with hypertension and tachycardia.SevereCommonAnecdotal
Seizures and hyperthermiaOverdose can cause agitation, seizures, hyperthermia and rhabdomyolysis.Life-threateningUncommonAnecdotal

07 References

NBF and NBOMe designer hallucinogens in forensic caseworkJournal of Analytical Toxicology, 2016
EMCDDA NBOMe/NBF overviewEMCDDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.